Aims Despite their ability to cause septic shock and myocardial dysfunction, components of Gramnegative bacterial cell walls, like lipopolysaccharide, have been shown in numerous studies to induce myocardial protection during ischaemia-reperfusion injury. Muramyl dipeptide (MDP) is another such component recognized by an intracellular receptor, nucleotide-binding oligomerization domain 2. Receptor activation leads to intracellular signals through receptor interacting protein-2 (RIP2) and tumour growth factor-b-activated kinase-1 (TAK1). However, little is known about the RIP2/TAK1 pathway in the heart. The aim of this study was to determine whether the RIP2/TAK1 pathway has a cardioprotective role in a mouse model of myocardial infarction.
Aims Despite their ability to cause septic shock and myocardial dysfunction, components of Gramnegative bacterial cell walls, like lipopolysaccharide, have been shown in numerous studies to induce myocardial protection during ischaemia-reperfusion injury. Muramyl dipeptide (MDP) is another such component recognized by an intracellular receptor, nucleotide-binding oligomerization domain 2. Receptor activation leads to intracellular signals through receptor interacting protein-2 (RIP2) and tumour growth factor-b-activated kinase-1 (TAK1). However, little is known about the RIP2/TAK1 pathway in the heart. The aim of this study was to determine whether the RIP2/TAK1 pathway has a cardioprotective role in a mouse model of myocardial infarction.
Methods and results We isolated and subjected wild-type (WT) and RIP2
2/2 mouse hearts to 30 min of global ischaemia and 120 min of reperfusion with or without perfusion of MDP (10 mg/mL) before or after the ischaemic period and determined the infarct size. We examined activation of the TAK1/ nuclear factor kB (NFkB) signalling pathway. The effect of TAK1 inhibition on MDP-induced cardioprotection was also evaluated. Exposure to MDP during reperfusion significantly reduced infarct size in WT hearts (from 51.7 + 5.6% in control to 38.1 + 6.7%, P , 0.05), but not in RIP2 2/2 hearts or in WT hearts with coincident pharmacological inhibition of TAK1. MDP treatment significantly increased the levels of p-TAK1 and p-JNK (Jun N-terminal kinase) and led to NFkB activation via phosphorylation and degradation of IkappaB in the WT, but not in the RIP2 2/2 , myocardium. Conclusion These results indicate that MDP at reperfusion induced cardioprotection through an RIP2/ TAK1-dependent mechanism.
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Introduction
Besides mechanical interventions like gradual or interrupted reperfusion, several studies have demonstrated that proteins including adipocytokines, insulin, and erythropoietin, 1, 2 when administered at the time of reperfusion, confer powerful cardioprotection. These effects could be attributable, in part, to the modulation of several kinases [phosphoinositide-3 kinase (PI3K), mitogen-activated protein (MAP) kinases, . . .] 3 which result in the recruitment of downstream antiapoptotic pathways promoting cell survival. These include the phosphorylation and inactivation of proapoptotic proteins. 4 Bacteria-derived ligands have paradoxical effects in biological systems. Despite their ability to cause septic shock and myocardial dysfunction, 5 numerous studies have shown that the Gram-negative bacterial cell wall component, lipopolysaccharide (LPS), induces myocardial protection during ischaemia-reperfusion injury. [6] [7] [8] This beneficial effect is mediated through pro-survival protein kinases, such as the PI3K/Akt-system, 9 and is not unique to LPS, since lipoteichoic acid, a cell wall component of Gram-positive bacteria, also reduces infarct size when administered before ischaemia. The effect of lipoteichoic acid is mediated through the Tolllike receptor pathway. 10 Muramyl dipeptide (MDP) is also a component of bacterial cell walls recognized by an intracellular receptor, nucleotide-binding oligomerization domain (NOD)-2. NOD2 activation led to intracellular signals through receptor interacting protein-2 (RIP2) and tumour growth factor-b-activated kinase-1 (TAK1) in non-cardiac tissue which modulated the nuclear factor kB (NFkB) pathway and promoted pro-inflammatory cytokine [interleukin-1b and tumour necrosis factor (TNF)-a] production. 11 However, little is known about the RIP2/TAK1 pathway in the heart. † These authors contributed equally to this work.
TAK1 is activated after acute myocardial infarction 12 and may play an important role in ventricular hypertrophy and heart failure.
13 RIP2 does not seem to influence myocardial sensitivity to infarction.
14 Moreover, the NOD2 receptor is present in the heart 15 and, like LPS, MDP contributes to septic shock, 16 which is in part the result of depressed cardiac contractility through RIP2 and p38 activation. 14 Thus, there is conflicting evidence on the potential beneficial role of MDP in different tissues and models. The aim of this study was to determine whether MDP has a cardioprotective role in a mouse model of myocardial infarction. Therefore, we perfused mouse hearts with MDP for 15 min before or after the ischaemic period and measured haemodynamic recovery and infarct size. We found that only pharmacological postconditioning with MDP is able to protect the heart against ischaemia-reperfusion injury and that this occurs via the RIP2/TAK1 pathway.
Methods

Products
MDP was from Invivogen, San Diego, CA, USA (catalog no. tlrl-mdp), and 5Z-7-oxozeanol (TAK1 inhibitor) was from Analyticon Discovery, Potsdam, Germany (catalog no. NP-009245). 
Animals
Experimental protocol for isolated murine myocardial infarction studies
Hearts were stabilized for 30 min after initiation of retrograde perfusion. For inclusion, all hearts had to fulfil the following criteria: CF between 1.5 and 4.5 mL/min, initial heart rate .300 bpm (unpaced), left ventricular developed pressure .55 mmHg, time from thoracotomy to aortic cannulation ,3 min, and no persistent dysrhythmias during the stabilization period. All hearts underwent 30 min of global ischaemia followed by 2 h of reperfusion. At the end of reperfusion, hearts were perfused for 1 min with 5 mL of 1% triphenyl tetrazolium chloride (TTC) in PBS and then placed in an identical solution at 378C for 10 min. The atria were then removed, and the hearts were blotted dry, weighed, and stored at 2208C. Hearts were subsequently thawed, placed in 2.5% glutaraldehyde for 1 min and set in 5% agarose. The agarose heart blocks were then sectioned from apex to base in 0.75 mm slices using a vibratome (Agar Scientific). Sections were compressed between glass plates and scan-imaged (Epson model G850A). After magnification, planimetry was carried out using image analysis software (Adobe Photoshop 7.0). Risk and infarct areas were calculated from surface area analysis of whole myocardium and TTC-negative myocardium, respectively. Infarct analysis was performed in all cases by an investigator blinded to the group assignments. 
Protocol
Our first objective was to assess the potential beneficial effect of pharmaceutical preconditioning with MDP to limit infarct size in WT mice.
The control group was perfused with Krebs buffer during the pre-and post-ischaemic phase. The preconditioning group was perfused with MDP (10 mg/mL) 15 min before ischaemia. All the hearts were stabilized for 30 min after initiation of retrograde perfusion and subjected to 30 min of ischaemia followed by 2 h of reperfusion ( Figure 1 ). Figure 1 Experimental protocols for ex vivo murine infarction studies in C57BL6 (WT) and RIP2 2/2 . All hearts were subjected to 30 min of stabilization, 30 min of global ischaemia, followed by 120 min of reperfusion at the end of which the infarct size was determined by triphenyl tetrazolium chloride staining. For the first protocol, muramyl dipeptide (MDP) was perfused 15 min before ischaemia (I-R MDP precond). In a second protocol, MDP was perfused immediately at the onset of reperfusion in the presence or absence of the TAK1 inhibitor (5Z-7-oxozeanol, 1 mmol/L).
Our second objective was to assess the potential beneficial effect of pharmaceutical postconditioning with MDP to limit infarct size in WT mice. WT and RIP2 2/2 mice were divided into three study groups, as shown in Figure 1 . In the control group (I-R), normal Krebs buffer was perfused during the pre-and post-ischaemic phase. In the MDP group (I-R MDP postcond), MDP (10 mg/mL) was perfused immediately at the onset of reperfusion for 15 min, followed by Krebs buffer alone for the remaining 105 min. The final group (I-R MDP 5-oxo) comprised the TAK1 inhibitor (5Z-7-oxozeanol, 1 mmol/L) with and without coincident MDP to determine the role of TAK1 in the postconditioning effect of MDP. The 5Z-7-oxozeanol (1 mmol/L) was perfused immediately at the onset of reperfusion for 15 min, followed by Krebs buffer alone for the remaining 105 min (Figure 1) .
For protein biochemistry, WT and RIP2 2/2 hearts were instantly frozen in liquid nitrogen after 5 min of reperfusion with or without MDP or 5Z-7-oxozeanol and stored at 280ºC before use. WT and RIP2
2/2 mouse hearts perfused for 65 min were used as a control group.
Immunoblotting
Samples were thawed and homogenized in protein extraction buffer (500 mmol/L NaCl, 50 mmol/L Tris-HCl, pH 7.5, 1 mmol/L EDTA, 1% (v/v) Triton X-100, 0.1% b-mercaptoethanol, 0.1% SDS, 5 mmol/L sodium orthovanadate, 10 mmol/L sodium fluoride, 10 mmol/L sodium pyrophosphate, and protease inhibitor tablets (Complete w , Roche Applied Science) (1 Tab/50 mL of buffer). One millilitre of extraction buffer was used per 100 mg of frozen tissue. Homogenates were centrifuged at 48C for 10 min at 13 000 rpm (15 600 g) and the clear supernatant kept for western blot analysis. Proteins were electrophoresed on a 10% polyacrylamide gel and then blotted onto a PVDF membrane. After blocking with 5% non-fat milk, the membranes were incubated with the following primary antibodies at dilutions of 1:1000 or 1:500 recognizing total p38 MAPK (catalog no. 9212), total TAK1 (catalog no. 4505 
Statistical analyses
All data are presented as means + SEM. Comparisons between groups were assessed for significance by analysis of variance (ANOVA) or repeated measures ANOVA, as appropriate. When significant differences were detected, individual mean values were compared by Bonferroni's post hoc test which allowed for multiple comparisons. P-values ,0.05 were considered significant.
Results
MDP treatment is cardioprotective at reperfusion but not before the ischaemic period
To determine whether MDP could have a cardioprotective effect in common with other components of the bacterial wall, we perfused mouse hearts with MDP for 15 min before the ischaemic period and measured haemodynamic recovery ( Table 1 ) and infarct size (Figure 2A) . Baseline coronary flow (CF) and contractile parameters were similar at the end of the stabilization period. The haemodynamic parameters remained the same before and after the 15 min perfusion of MDP (10 mg/mL). MDP treatment did not change the haemodynamic parameters compared with the control group, and the infarct size after 2 h was the same in control and MDP pre-ischaemia groups. Preconditioning and postconditioning have been widely studied and there is evidence that there are common and specific signalling pathways involved in these cardioprotective mechanisms. So we looked at the role of MDP at reperfusion as a postconditioning agent. MDP was administered for 15 min at the onset of reperfusion, and haemodynamic recovery ( Table 2 ) and infarct size ( Figure 2B) were measured. Baseline CF and contractile parameters were similar at the end of the stabilization period. However, when MDP was administered after the ischaemic period, the developed pressure after 2 h of reperfusion had increased by 50.2% (P , 0.05) over the control group. This recovery was reflected in the infarct size in MDP-exposed hearts, which was reduced from 51.7 + 5.6% in control to 38.1 + 6.7%, P , 0.05 ( Figure 2B ).
MDP is acting through RIP2
MDP has been described as a ligand of the NOD2 receptor and acts via the recruitment of RIP2 protein. To identify whether RIP2 is implicated in the cardioprotective effect of MDP, we perfused RIP2 2/2 mice. In mice lacking RIP2, the protective effects of MDP are absent (Table 2 and Figure 2B ). Thus, RIP2 is necessary for cardioprotection with MDP.
TAK1 activity is cardioprotective
Upon activation, RIP2 has been described to form a complex with other proteins including TAK1 and TNF receptorassociated factor 6. To determine the relevance of this axis to our observation, we perfused mouse hearts with the TAK1 inhibitor 5Z-7-oxozeanol at the onset of reperfusion.
5Z-7-Oxozeanol abolished the decrease in the infarct size observed in the MDP-treated hearts (38.1 + 6.7% in MDP vs. 50.6 + 6.1% with MDP þ 5Z-7-oxozeanol, P , 0.05; Figure 2B ), indicating that TAK1 is required for MDP's cardioprotective effect. It is of interest to note that the administration of 5Z-7-oxozeanol alone significantly increased infarct size (65.6 + 9.6% vs. 51.7 + 5.6%, P , 0.05), suggesting a potential role for TAK1 in the modulation of infarction in the absence of MDP. To rule out any nonspecific toxic effect of the 5Z-7-oxozeanol, we perfused the TAK1 inhibitor alone for 15 min and we did not notice any alteration of contractility (data not shown).
Biochemical analysis of the cardioprotective effect
To better understand the mechanisms responsible for the cardioprotective effect of MDP during reperfusion, we examined the activation of the known proteins downstream of RIP2: TAK1, JNK, and MKK.
As previously published, ischaemia-reperfusion in WT mice triggers the activation of many kinases including TAK1 and JNK ( Figure 3, left panel) . MDP exposure at reperfusion was able to increase the activating phosphorylation of TAK1 and JNK (Figure 3) . In RIP2 2/2 mice ( Figure 3 , right panel), TAK1 phosphorylation states were similar with or without ischaemia; however, JNK was more phosphorylated during the reperfusion phase. MDP was not able to modify TAK1 or JNK phosphorylation in the RIP2 2/2 mice. To be sure that the perfusion of TAK1 inhibitor 5Z-7-oxozeanol was effective, we probed for the autophosphorylation site of TAK1 (Thr187) (Figure 4) , the diminution of phosphorylation confirms pharmacological inhibition of TAK1 and MKK7 during reperfusion.
The role of glycogen synthase kinase (GSK)3b in postconditioning is a matter of debate and has been implicated by some groups 20, 21 but not by others 22 nor by our own lab. 23 Nonetheless, we decided to check whether the GSK3 pathway could be linked to MDP-mediated protection. We looked at GSK3b phosphorylation and its upstream partner Akt. Both are phosphorylated during reperfusion; however, no difference was observed in the presence of MDP, indicating that GSK3b or Akt involvement is unlikely (data not shown).
MDP modulation of NFkB signalling
Myocardial cardioprotection conferred by modulation of cytokine production via NFkB and TAK1 has been linked to direct phosphorylation of the IkappaB kinase (IKK) complex, which in turn phosphorylates IkBa. 24 IkBa binds to NFkB and sequesters it in the cytosol, preventing its role as a transcription factor. After phosphorylation by IKK complex, IkBa is rapidly degraded, and released NFkB can translocate to the nucleus where it drives the expression of many genes. 25 We wanted to elucidate whether MDP-TAK1 cardioprotection signals through NFkB. In Figure 5 , we studied IkBa phosphorylation and the level of total IkBa after ischaemia-reperfusion with or without MDP. In the WT, IkBa was phosphorylated during reperfusion, an effect enhanced by MDP. The IkBa protein was degraded in the presence of MDP as reflected by a reduction in total IkBa. In the RIP2 2/2 mice, the IkBa phosphorylation level was similar between control and ischaemia/reperfusion with or without MDP and IkBa protein did not seem to be degraded. These results indicate that the modulation of the NFkB pathway may be involved in cardioprotection by MDP.
Discussion
The major finding in this study is that MDP at reperfusion induced cardioprotection, mediated via an RIP2/TAK1-dependent mechanism. We demonstrated that administration of a pharmacological inhibitor of TAK1 abrogated the protective postconditioning effect of MDP in myocardial I/R injury. We also showed that the cardioprotective effect of MDP administrated during reperfusion was abolished in RIP2 null hearts. Thus, RIP2 and TAK1 are involved in MDP-initiated postconditioning. Furthermore, our data suggest that the activation of several downstream kinases (such as MKK7/JNK pathway) results directly, or indirectly, in the modulation of NFkB activation. To our knowledge, this is the first report which causally links MDP-induced cardioprotection with the RIP2/TAK1 signalling pathway.
In our previous study, 14 we did not find any evidence that RIP2 contributed to the development of myocardial infarction; however, RIP2 may be involved in the myocardial response to MDP. LPS and MDP are both components of bacterial cell wall that act synergistically, so it is possible that some cardioprotective pathways activated by LPS such as Akt, ERK, and IKKb could be shared by MDP. Previous studies have shown that pre-treatment of animals with a low dose of LPS for 24 h results in protection against I/R injury through the PI3K/Akt pathway. 9 The role of MDP after acute myocardial ischaemia has been studied in vivo in a different protocol and shown to facilitate infarct expansion in association with the promotion of monocyte recruitment and inappropriate collagen synthesis. 26 But in our hands in a different species and model with a different protocol where monocyte recruitment was impossible, we demonstrated a cardioprotective effect of MDP. It is interesting to note that in addition to LPS, the toll-like receptor-4 recognizes heat shock proteins (Hsp-60 and Hsp-70) that are produced in response to myocardial ischaemia and confer potent cardioprotective effects in the heart. So further studies are necessary to delineate the complex cardioprotective effect of MDP and identify possible common partners with the better characterized LPS cardioprotective pathway (for review, see Chao 27 ). Another cardioprotective pathway GSK3b and other reperfusion injury salvage kinase (RISKs) have been implicated by others in postconditioning, 20, 21 but in our previous study 23 and in the current study, we could not associate the cardioprotective effect of MDP with GSK3b inactivation. This controversial observation may be explained by in vivo vs. ex vivo models, different triggers of protection (isoflurane vs. MDP) or temporal variations (duration of I/R cycle) in the postconditioning protocol. In this study, by inhibiting TAK1 activity with 5Z-7-oxozeanol, we revealed the cardioprotective role of TAK1. TAK1 has already been associated with cell survival in other compartments, i.e. osteoclast cells, 28 and studies in adult mouse myocardium, where TAK1 is activated after aortic banding, and was sufficient to provoke heart failure. 29 Thus, the role of TAK1 in heart pathophysiology is likely complex with an early cardioprotective role during short-term activation over minutes during ischaemia-reperfusion but a possible deleterious role with more prolonged activation over days. Superficially, at least, it seems surprising that TAK1 activation can be beneficial. However, the suggested paradigm of brief activation having a beneficial consequence is very similar to that seen in the related TNF signalling cascade. Here, it is clear that prolonged TNF exposure leads to cardiac dilatation, heart failure, and premature death, 30 in a manner analogous to chronic TAK1 activation, 29 while brief exposure is cardioprotective. 31 Since postconditioning could be useful for clinicians, the identification of a new mechanism of postconditioning is valuable. Obviously, the direct use of MDP in patients is unlikely but the modulation of the signalling pathway identified in this study could be the target for new cardioprotective drugs. Further studies are required to determine the safety of modulation of RIP2/TAK1 pathway in an in vivo model and whether other survival kinases activated at the time of myocardial reperfusion contribute to the protection observed in the postconditioned heart.
